Mary Wilson
Well-known member
Published: April 12, 2023
DOI:https://doi.org/10.1016/S1473-3099(23)00068-3
Daniel Jenkin, MRCP [SUP]† [/SUP]Daniel Wright, DPhil [SUP]† [/SUP]Pedro M Folegatti, DPhil Abigail Platt, BN Ian Poulton, DipHE Alison Lawrie, PhD et al.
Summary
Background
Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We aimed to evaluate the safety and immunogenicity of a non-replicating simian adenovirus-vectored Rift Valley fever (ChAdOx1 RVF) vaccine in humans.
Methods
We conducted a phase 1, first-in-human, open-label, dose-escalation trial in healthy adults aged 18–50 years at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford, UK. Participants were required to have no serious comorbidities or previous history of receiving an adenovirus-based vaccine before enrolment. Participants were non-randomly allocated to receive a single ChAdOx1 RVF dose of either 5 × 10[SUP]9[/SUP] virus particles (vp), 2·5 × 10[SUP]10[/SUP] vp, or 5 × 10[SUP]10[/SUP] vp administered intramuscularly into the deltoid of their non-dominant arm; enrolment was sequential and administration was staggered to allow for safety to be assessed before progression to the next dose. Primary outcome measures were assessment of adverse events and secondary outcome measures were Rift Valley fever neutralising antibody titres, Rift Valley fever GnGc-binding antibody titres (ELISA), and cellular response (ELISpot), analysed in all participants who received a vaccine. This trial is registered with ClinicalTrials.gov(NCT04754776).
Findings
Between June 11, 2021, and Jan 13, 2022, 15 volunteers received a single dose of either 5 × 10[SUP]9[/SUP] vp (n=3), 2·5 × 10[SUP]10[/SUP] vp (n=6), or 5 × 10[SUP]10[/SUP] vp (n=6) ChAdOx1 RVF. Nine participants were female and six were male. 14 (93%) of 15 participants reported solicited local adverse reactions; injection-site pain was the most frequent (13 [87%] of 15). Ten (67%) of 15 participants (from the 2·5 × 10[SUP]10[/SUP] vp and 5 × 10[SUP]10[/SUP] vp groups only) reported systemic symptoms, which were mostly mild in intensity, the most common being headache (nine [60%] of 15) and fatigue (seven [47%]). All unsolicited adverse events reported within 28 days were either mild or moderate in severity; gastrointestinal symptoms were the most common reaction (at least possibly related to vaccination), occurring in four (27%) of 15 participants. Transient decreases in total white cell, lymphocyte, or neutrophil counts occurred at day 2 in some participants in the intermediate-dose and high-dose groups. Lymphopenia graded as severe occurred in two participants in the 5 × 10[SUP]10[/SUP] vp group at a single timepoint, but resolved at the subsequent follow-up visit. No serious adverse events occurred. Rift Valley fever neutralising antibodies were detectable across all dose groups, with all participants in the 5 × 10[SUP]10[/SUP] vp dose group having high neutralising antibody titres that peaked at day 28 after vaccination and persisted through the 3-month follow-up. High titres of binding IgG targeting Gc glycoprotein were detected whereas those targeting Gn were comparatively low. IFNγ cellular responses against Rift Valley fever Gn and Gc glycoproteins were observed in all participants except one in the 5 × 10[SUP]10[/SUP] vp dose group. These IFNγ responses peaked at 2 weeks after vaccination, were highest in the 5 × 10[SUP]10[/SUP] vp dose group, and tended to be more frequent against the Gn glycoprotein.
Interpretation
ChAdOx1 RVF was safe, well tolerated, and immunogenic when administered as a single dose in this study population. The data support further clinical development of ChAdOx1 RVF for human use.
https://www.thelancet.com/action/showPdf?pii=S1473-3099(23)00068-3
DOI:https://doi.org/10.1016/S1473-3099(23)00068-3
Daniel Jenkin, MRCP [SUP]† [/SUP]Daniel Wright, DPhil [SUP]† [/SUP]Pedro M Folegatti, DPhil Abigail Platt, BN Ian Poulton, DipHE Alison Lawrie, PhD et al.
Summary
Background
Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We aimed to evaluate the safety and immunogenicity of a non-replicating simian adenovirus-vectored Rift Valley fever (ChAdOx1 RVF) vaccine in humans.
Methods
We conducted a phase 1, first-in-human, open-label, dose-escalation trial in healthy adults aged 18–50 years at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford, UK. Participants were required to have no serious comorbidities or previous history of receiving an adenovirus-based vaccine before enrolment. Participants were non-randomly allocated to receive a single ChAdOx1 RVF dose of either 5 × 10[SUP]9[/SUP] virus particles (vp), 2·5 × 10[SUP]10[/SUP] vp, or 5 × 10[SUP]10[/SUP] vp administered intramuscularly into the deltoid of their non-dominant arm; enrolment was sequential and administration was staggered to allow for safety to be assessed before progression to the next dose. Primary outcome measures were assessment of adverse events and secondary outcome measures were Rift Valley fever neutralising antibody titres, Rift Valley fever GnGc-binding antibody titres (ELISA), and cellular response (ELISpot), analysed in all participants who received a vaccine. This trial is registered with ClinicalTrials.gov(NCT04754776).
Findings
Between June 11, 2021, and Jan 13, 2022, 15 volunteers received a single dose of either 5 × 10[SUP]9[/SUP] vp (n=3), 2·5 × 10[SUP]10[/SUP] vp (n=6), or 5 × 10[SUP]10[/SUP] vp (n=6) ChAdOx1 RVF. Nine participants were female and six were male. 14 (93%) of 15 participants reported solicited local adverse reactions; injection-site pain was the most frequent (13 [87%] of 15). Ten (67%) of 15 participants (from the 2·5 × 10[SUP]10[/SUP] vp and 5 × 10[SUP]10[/SUP] vp groups only) reported systemic symptoms, which were mostly mild in intensity, the most common being headache (nine [60%] of 15) and fatigue (seven [47%]). All unsolicited adverse events reported within 28 days were either mild or moderate in severity; gastrointestinal symptoms were the most common reaction (at least possibly related to vaccination), occurring in four (27%) of 15 participants. Transient decreases in total white cell, lymphocyte, or neutrophil counts occurred at day 2 in some participants in the intermediate-dose and high-dose groups. Lymphopenia graded as severe occurred in two participants in the 5 × 10[SUP]10[/SUP] vp group at a single timepoint, but resolved at the subsequent follow-up visit. No serious adverse events occurred. Rift Valley fever neutralising antibodies were detectable across all dose groups, with all participants in the 5 × 10[SUP]10[/SUP] vp dose group having high neutralising antibody titres that peaked at day 28 after vaccination and persisted through the 3-month follow-up. High titres of binding IgG targeting Gc glycoprotein were detected whereas those targeting Gn were comparatively low. IFNγ cellular responses against Rift Valley fever Gn and Gc glycoproteins were observed in all participants except one in the 5 × 10[SUP]10[/SUP] vp dose group. These IFNγ responses peaked at 2 weeks after vaccination, were highest in the 5 × 10[SUP]10[/SUP] vp dose group, and tended to be more frequent against the Gn glycoprotein.
Interpretation
ChAdOx1 RVF was safe, well tolerated, and immunogenic when administered as a single dose in this study population. The data support further clinical development of ChAdOx1 RVF for human use.
https://www.thelancet.com/action/showPdf?pii=S1473-3099(23)00068-3